Abstract:Background: Metabolomics has the potential to provide putative biomarkers and insights into the pathophysiology and diagnosis of pediatric multiple sclerosis (pMS), which is an inflammatory demyelinating disorder of the central nervous system with a broad spectrum of clinical manifestations. In this study, we aimed to investigate serum metabolomics in pMS to help elucidate the pathophysiology of MS. Methods: An untargeted approach was applied using the quadrupole time-of-flight liquid chromatography/mass spectrometry (Q-TOF LC/MS) method to study plasma metabolites in patients with pMS (n = 33), patients with unclassified central nervous system demyelinating diseases (n = 6), and age-matched healthy control subjects (n = 40). The patient and control groups were compared for metabolites and the normalized peak areas differed statistically (p < 0.05), showing at least a 1.25-fold change between groups. Bioinformatic tools combined with a clinical perspective were employed for the identification of the putative metabolites. In addition to the untargeted metabolomics approach, targeted LC-MS/MS metabolite analysis was employed to compare the pMS group with the control group. Results: Significant differences between the patient and control groups were noted for tyramine, 4-hydroxyphenylacetaldehyde, sphingosine/3-dehydrosphinganine, prostaglandins/thromboxane A2, 20-hydroxy-leukotriene E4, 3α,7α,12α-trihydroxy-5β-cholestan26-al/calcitriol, pantetheine, ketoleucine/3-methyl-2-oxovaleric acid, L-arginine/D-arginine, coproporphyrinogen III, (S)-reticuline, carnosine, cytidine, and phosphoribosyl pyrophosphate. Additional tests for sphingosine 1-phosphate, sphingophosphocholines, ceramides, oxysterols, and calcitriol levels yielded significant metabolomic differences for the pMS group compared to the control group. The metabolomic data of 3/6 patients with unclassified demyelinating disorders matched the pMS group; their follow-up verified the diagnosis of pMS. Discussion: In general, plasma metabolites related to sphingolipid metabolism, myelin products, inflammatory pathways, mitochondrial dysfunction, and oxidative stress were found to be altered in cases of pMS. The method applied in this study, combining untargeted analysis with a targeted approach, can be applied to larger series of cases of pMS and other demyelinating disorders for further validation.

Multi-omics profiling reveals peripheral blood biomarkers of multiple sclerosis: implications for diagnosis and stratification

Quantitative proteomics and multi-omics analysis identifies potential biomarkers and the underlying pathological molecular networks in Chinese patients with multiple sclerosis

Integrated omics profiling reveals systemic dysregulation and potential biomarkers in the blood of patients with neuromyelitis optica spectrum disorders

Altered Plasma Metabolic Profiles in Chinese Patients With Multiple Sclerosis

Cerebrospinal Fluid Oligoclonal Bands in Chinese Patients with Multiple Sclerosis: the Prevalence and Its Association with Clinical Features

Microarray gene expression profiling analysis combined with bioinformatics in multiple sclerosis

Multi-parametric MRI Phenotype with Trustworthy Machine Learning for Differentiating CNS Demyelinating Diseases

Quantitative Proteomic Analysis of the Cerebrospinal Fluid of Patients with Multiple Sclerosis

Mass Cytometry Identifies Expansion of T-bet+ B Cells and CD206+ Monocytes in Early Multiple Sclerosis

Multi-omics integration prioritizes potential drug targets for multiple sclerosis

Imaging Transcriptomics of Brain Functional Alterations in MS and Neuromyelitis Optica Spectrum Disorder

Single-Cell Transcriptome Profiling Unravels Distinct Peripheral Blood Immune Cell Signatures of RRMS and MOG Antibody-Associated Disease

Targeted proteomics of cerebrospinal fluid in treatment naïve multiple sclerosis patients identifies immune biomarkers of clinical phenotypes

Peripheral Inflammatory and Immune Landscape in Multiple System Atrophy: A Cross-Sectional Study

A combination of Q-TOF LC/MS and LC-MS/MS based metabolomics in pediatric-onset multiple sclerosis demonstrates potential biomarkers for unclassified patients

Integrated single-cell transcriptomics of cerebrospinal fluid cells in treatment-naïve multiple sclerosis

Machine learning-driven diagnosis of multiple sclerosis from whole blood transcriptomics

Combining gene expression microarrays and Mendelian randomization: exploring key immune-related genes in multiple sclerosis

Gut Dysbiosis and Lack of Short Chain Fatty Acids in a Chinese Cohort of Patients with Multiple Sclerosis

Integrating Genetic and Proteomic Data to Elucidate the Association Between Immune System and Blood-Brain Barrier Dysfunction with Multiple Sclerosis Risk and Severity

Utilising multi-large omics data to elucidate biological mechanisms within multiple sclerosis genetic susceptibly loci